In addition to the findings of any lab test suggesting the presence of a communicable disease, the director of a medical lab must also submit microbiologic cultures, subcultures, culture-independent diagnostic tests or other specimens or clinical material to the State Public Health Laboratory.
Qualified laboratories, offices of providers, and medical facilities shall report any result of a blood test for lead screening obtained by using a capillary specimen and which indicates an amount of lead in the blood that is greater than the amount designated by the Council of State and Territorial Epidemiologists.
Laboratories who are processing and testing samples from Nevada residents are required under severe penalties to report all COVID-19 test results to the Division of Public and Behavioral Health within 24 hours from analysis through an established reporting method. *New*: Laboratories must additionally submit all positive samples of SARS-Co-V-2 with a cycle threshold of (Ct) <30 to the Nevada State Public Health Laboratory for genomic sequencing. *New as of end of day May 11, 2023*: As a result of ending the PHE declaration, the Coronavirus Aid, Relief, and Economic Security (CARES) Act authority for HHS to require laboratory result reporting will be revoked. In response, the COVID-19 laboratory result reporting requirement within Nevada will change. As of the end of the day on May 11, 2023, negative and inconclusive COVID-19 results will no longer be required to be reported regardless of the type of test performed. All positive COVID-19 results will continue to be reportable with the exception of self-administered at-home tests and serology testing. (See attached TB.)
The director or other person in charge of a medical laboratory shall report as required by this section the results of any test confirming the presence of the human immunodeficiency virus (HIV) or antibodies to the human immunodeficiency virus (HIV); or if the test was conducted to monitor the progression of a human immunodeficiency virus (HIV) infection, including, without limitation, all levels of CD4, and both detectable and undetectable viral loads.
Facilities must report patient death or serious injury resulting from the irretrievable loss of an irreplaceable biological specimen, including events where specimens are misidentified, where another procedure cannot be done to produce a specimen, and including progression of an undiagnosed disease or threat of disease that changes the patient's risk status for life, requiring monitoring not needed before the event.
Facilities must report patient death or serious injury resulting from failure to follow up or communicate laboratory, pathology, or radiology test results. Includes events where failure to report increased neonatal bilirubin levels result in kernicterus. Examples of serious injury are a new diagnosis, or an advancing stage of an existing diagnosis (e.g., cancer). Failure to follow up or communicate can be limited to healthcare staff or can involve communication to the patient.
Hospitals, medical laboratories and other facilities that provide screening, diagnostic or therapeutic services to patients with respect to cancer and other neoplasms shall report information on cases of cancer and other neoplasms, which are specified by the State Board of Health as subject to reporting, to the system.